FCCC LOGO Faculty Publications
Integration of Immunotherapy Into the Treatment of Advanced Urothelial Carcinoma
J Natl Compr Canc Netw. 2020 Mar;18(3) :355-361
Back to previous list
Abstract
Five new PD-1/PD-L1 checkpoint inhibitors have been approved for the treatment of metastatic urothelial carcinoma (UC): pembrolizumab, atezolizumab, durvalumab, nivolumab, and avelumab. Although cisplatin-based chemotherapy remains the recommended frontline option for cisplatin-eligible patients with metastatic UC, immunotherapy is now an available option in the second-line setting as well as the frontline setting for selected cisplatin-ineligible patients who are either unable to tolerate chemotherapy or PD-L1-positive. This review describes the updated clinical efficacy of these checkpoint inhibitors in the treatment of advanced UC and suggests how they can be sequenced in the context of available chemotherapeutic options.
Notes
1540-1413 Ghatalia, Pooja Plimack, Elizabeth R Journal Article Review United States J Natl Compr Canc Netw. 2020 Mar;18(3):355-361. doi: 10.6004/jnccn.2020.7539.